Literature DB >> 8255468

Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis.

D Kidd1, J W Thorpe, A J Thompson, B E Kendall, I F Moseley, D G MacManus, W I McDonald, D H Miller.   

Abstract

We performed MRI of brain and spinal cord on 80 patients with multiple sclerosis (MS). Using multi-array coils and fast spin echo, 139 intrinsic lesions were identified in 59 patients (74%). Lesions were more common in the cervical than in the thoracic cord. Cross-sectional areas of the cord, measured from axial images at four levels, showed atrophy in 40%. Clinical disability correlated with cord atrophy but not with cord lesion load. These results show that the use of multi-array coils and fast spin echo allows rapid and sensitive detection of spinal cord lesions in MS and that the cord is involved in the majority of patients. A lack of association between cord lesions and disability may relate to limitations in MR resolution but also suggests that the mechanisms of disability in MS are complex and multifactorial.

Entities:  

Mesh:

Year:  1993        PMID: 8255468     DOI: 10.1212/wnl.43.12.2632

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  79 in total

1.  Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis.

Authors:  D B McGavern; P D Murray; C Rivera-Quiñones; J D Schmelzer; P A Low; M Rodriguez
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

Review 2.  Neurological rehabilitation: from mechanisms to management.

Authors:  A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-12       Impact factor: 10.154

3.  Improved Lesion Detection by Using Axial T2-Weighted MRI with Full Spinal Cord Coverage in Multiple Sclerosis.

Authors:  S Galler; J-P Stellmann; K L Young; D Kutzner; C Heesen; J Fiehler; S Siemonsen
Journal:  AJNR Am J Neuroradiol       Date:  2016-01-07       Impact factor: 3.825

4.  Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy.

Authors:  Carsten Lukas; Barbara Bellenberg; Horst K Hahn; Jan Rexilius; Robert Drescher; Kerstin Hellwig; Odo Köster; Sebastian Schimrigk
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

5.  [Revision of McDonald's new diagnostic criteria for multiple sclerosis].

Authors:  H Wiendl; B C Kieseier; R Gold; R Hohlfeld; M Bendszus; H-P Hartung
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

6.  Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study.

Authors:  J M Stankiewicz; M Neema; D C Alsop; B C Healy; A Arora; G J Buckle; T Chitnis; C R G Guttmann; D Hackney; R Bakshi
Journal:  J Neurol Sci       Date:  2009-04-15       Impact factor: 3.181

7.  Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.

Authors:  Jiwon Oh; Shiv Saidha; Min Chen; Seth A Smith; Jerry Prince; Craig Jones; Marie Diener-West; Peter C M van Zijl; Daniel S Reich; Peter A Calabresi
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

8.  Axonal degeneration and progressive neurologic disability in multiple sclerosis.

Authors:  Carl Bjartmar; Bruce D Trapp
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study.

Authors:  Y Zoukos; T N Thomaides; D Kidd; M L Cuzner; A Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

10.  Magnetic resonance imaging of spinal pyramidal tract degeneration in amyotrophic lateral sclerosis.

Authors:  S Terao; G Sobue; T Yasuda; T Kachi; N Shimada; C Oguri; T Mitsuma
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.